Google_______________

ALT Levels Prior to Pregnancy Predict Risk of HCV Vertical Transmission

By Liz Highleyman

Mother-to-child transmission of the hepatitis C virus (HCV) may occur during pregnancy or delivery. Most studies indicate that the overall rate of perinatal transmission is low -- less than 5% -- but various factors can increase the risk, including high maternal HCV viral load and coinfection with HIV.

According to a study reported in the July 2006 Journal of Medical Virology, the mother's alanine transaminase (ALT) level during the year before pregnancy may also predict the risk of vertical HCV transmission.

The analysis included 74 mothers who transmitted HCV to their infants and 403 HCV positive mothers who did not. All enrolled women received two ALT measurements, at least six months apart, in the year before they became pregnant.

The researchers categorized the women into one of two groups:

Normal: those with persistently normal serum ALT levels;

Abnormal: those with either consistently elevated ALT (more than twice the upper limit of normal) or fluctuating ALT levels (one normal and one elevated measurement).

Results

52.7% of mothers (39 out of 74) who transmitted HCV had abnormal ALT levels, compared with 32.6% mothers (146 out of 403) who did not transmit the virus (P = 0.008; relative risk 1.96; 95% CI 1.19-3.23).

Mothers with consistently elevated ALT were more likely to transmit HCV than those with fluctuating ALT levels.

Conclusion

The authors concluded that increased ALT levels may reflect more severe liver disease and a higher viral load, which is known to be associated with an increased risk of vertical transmission. They suggested that the inexpensive and widely available ALT test may help identify mothers with an increased risk of HCV vertical transmission, which could be particularly beneficial in settings where more expensive laboratory tests (such as HCV RNA) are unavailable or unaffordable.

7/21/06

Reference
G Indolfi, C Azzari, M Moriondo, and others. Alanine transaminase levels in the year before pregnancy predict the risk of hepatitis C virus vertical transmission. Journal of Medical Virology 78(7): 911-914. July 2006.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin